181 related articles for article (PubMed ID: 28872911)
41. Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug.
Ortiz JF; Khan SA; Salem A; Lin Z; Iqbal Z; Jahan N
Cureus; 2020 Oct; 12(10):e10818. PubMed ID: 33173626
[TBL] [Abstract][Full Text] [Related]
42. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis.
Martinez A; Palomo Ruiz MD; Perez DI; Gil C
Expert Opin Investig Drugs; 2017 Apr; 26(4):403-414. PubMed ID: 28277881
[TBL] [Abstract][Full Text] [Related]
43. Clinical trials in amyotrophic lateral sclerosis.
McDermott CJ
Curr Opin Neurol; 2019 Oct; 32(5):758-763. PubMed ID: 31335338
[TBL] [Abstract][Full Text] [Related]
44. [Edaravone: A New Treatment for ALS].
Yamashita T; Abe K
Brain Nerve; 2019 Nov; 71(11):1245-1251. PubMed ID: 31722310
[TBL] [Abstract][Full Text] [Related]
45. Edaravone inhibits the disease activity in rheumatoid arthritis.
Arii K; Kumon Y; Ikeda Y; Suehiro T; Hashimoto K
J Clin Pharm Ther; 2006 Apr; 31(2):197-9. PubMed ID: 16635056
[TBL] [Abstract][Full Text] [Related]
46. New Oral Form for ALS Drug.
Aschenbrenner DS
Am J Nurs; 2022 Sep; 122(9):24-25. PubMed ID: 36005791
[TBL] [Abstract][Full Text] [Related]
47. [Edaravone].
Abe K
Nihon Rinsho; 2006 Oct; 64 Suppl 7():548-53. PubMed ID: 17461204
[No Abstract] [Full Text] [Related]
48. A multiple free-radical scavenging (MULTIS) study on the antioxidant capacity of a neuroprotective drug, edaravone as compared with uric acid, glutathione, and trolox.
Kamogawa E; Sueishi Y
Bioorg Med Chem Lett; 2014 Mar; 24(5):1376-9. PubMed ID: 24507926
[TBL] [Abstract][Full Text] [Related]
49. Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone.
Kakimoto A; Ishizaki M; Ueyama H; Maeda Y; Ueda M
Medicine (Baltimore); 2021 May; 100(21):e26127. PubMed ID: 34032759
[TBL] [Abstract][Full Text] [Related]
50. Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics.
Breiner A; Zinman L; Bourque PR
CMAJ; 2020 Mar; 192(12):E319-E320. PubMed ID: 32392516
[No Abstract] [Full Text] [Related]
51. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
52. ALS Untangled No.33 Endotherapia.
ALSUntangled Group
Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(5-6):461-5. PubMed ID: 26808361
[No Abstract] [Full Text] [Related]
53. Edaravone, a free radical scavenger, retards the development of amygdala kindling in rats.
Kamida T; Abe E; Abe T; Ooba H; Fujiki M; Kobayashi H
Neurosci Lett; 2009 Sep; 461(3):298-301. PubMed ID: 19545611
[TBL] [Abstract][Full Text] [Related]
54. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe.
Takei K; Tsuda K; Takahashi F; Hirai M; Palumbo J
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):88-97. PubMed ID: 28872912
[TBL] [Abstract][Full Text] [Related]
55. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial).
Shinohara Y; Saito I; Kobayashi S; Uchiyama S
Cerebrovasc Dis; 2009; 27(5):485-92. PubMed ID: 19321945
[TBL] [Abstract][Full Text] [Related]
56. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.
Gladman M; Cudkowicz M; Zinman L
Curr Opin Neurol; 2012 Dec; 25(6):735-42. PubMed ID: 23160423
[TBL] [Abstract][Full Text] [Related]
57. Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction.
Shinohara Y; Inoue S
J Stroke Cerebrovasc Dis; 2013 Jul; 22(5):668-74. PubMed ID: 22622391
[TBL] [Abstract][Full Text] [Related]
58. Edaravone, a free radical scavenger, in the treatment of idiopathic sudden sensorineural hearing loss with profound hearing loss.
Sano H; Kamijo T; Ino T; Okamoto M
Auris Nasus Larynx; 2010 Feb; 37(1):42-6. PubMed ID: 19570630
[TBL] [Abstract][Full Text] [Related]
59. The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Ogawa A; Iwata Y; Ogawa F; Takenaka M; Shimizu K; Asano Y; Kadono T; Sato S
Arthritis Rheum; 2011 Oct; 63(10):3086-97. PubMed ID: 21618208
[TBL] [Abstract][Full Text] [Related]
60. Drug therapy: On the treatment trail for ALS.
Scott A
Nature; 2017 Oct; 550(7676):S120-S121. PubMed ID: 29045376
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
